Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

  • Interventional
  • Not Recruiting
  • NCT01742988
Eligibility Details Visit Clinicaltrials.gov

Phase 1/2 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma

This is a phase 1/2, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory lymphoma, relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 alterations. Fimepinostat (CUDC-907) is a multi-targeted agent designed to inhibit phosphoinositide 3-kinase (PI3K)and histone deacetylase (HDAC). The study is designed to assess the safety, the maximum tolerated dose, the recommended phase 2 dose (RP2D), pharmacokinetics and the anti-cancer activity of oral fimepinostat in combination with 1 or more anti-cancer regimens.

Gender
All

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

Inclusion Criteria:

        Subjects of ≥ 18 years of age with any of the following:

        For Dose-Escalation cohorts:

         - Fimepinostat + venetoclax: Histopathologically confirmed DLBCL or HGBL that is refractory to, or has relapsed after, treatment with at least 1 prior regimen

         - Fimepinostat + rituximab + bendamustine: Histopathologically confirmed diagnosis of lymphoma (i.e., B-cell non-Hodgkin lymphoma [NHL], TCL, or HL) that is refractory to, or has relapsed after, treatment with at least 1 prior regimen.

        For Dose-Expansion cohorts:

         - Fimepinostat + venetoclax: R/R DLBCL or HGBL with both MYC and BCL2 alterations and/or overexpression (DHL, THL, or DEL) that is refractory to, or has relapsed after, 1 or more prior lines of therapy.

         - Fimepinostat + rituximab + bendamustine: R/R DLBCL or HGBL that is refractory to, or has relapsed after, 1 or more prior lines of therapy

         - Measurable disease by CT or PET/CT. MRI acceptable as per protocol.• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

         - Recovery to Grade 1 or baseline of any toxicity due to prior systemic treatments (excluding alopecia).

         - Absolute neutrophil count ≥ 1,000/µL; platelets ≥ 75,000/µL for patients with no bone marrow involvement by malignancy; platelets ≥ 50,000/µL for patients with bone marrow involvement by malignancy.

         - Creatinine ≤ 1.5x upper limit of normal (ULN); total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN.

         - Life expectancy of at least 3 months.

        Exclusion Criteria:

         - Intention to undergo stem cell transplant or treatment with chimeric antigen receptor (CAR) T-cell therapy.

         - Systemic anti-cancer therapy or investigational agent within 3 weeks of study entry, except for nitrosoureas or mitomycin C (6 weeks).

         - Other non-cytotoxic anti-cancer therapy or investigational agent within 5 half-lives or 21 days prior to study treatment, whichever is shorter, as long as any drug related toxicities have resolved to Grade 1 or less. Dexamethasone up to 12 mg/d is allowed as supportive therapy and does not exclude participation.

         - Graft vs. host disease following prior allogeneic transplant within 3 months prior to study treatment.

         - Ongoing treatment with chronic immunosuppressants.

         - Active CNS lymphoma.

         - Known gastrointestinal condition that would interfere with swallowing or the oral absorption or tolerance of fimepinostat.

         - Serious infection requiring systemic antibiotic therapy within 14 days prior to study treatment.

         - Uncontrolled or severe cardiovascular disease

         - Unstable or clinically significant concurrent medical condition.

         - Second primary malignancy within 2 years of study entry other than what is specified in the protocol.

         - Known HIV positive, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.

         - Active CMV infection, presence of CMV antigenemia, or evidence of any invasive CMV end organ disease (e.g., CMV colitis).

At a Glance

National Government IDNCT01742988

IRB#IRB19-0270

Lead SponsorCuris, Inc.

Lead PhysicianSonali Smith

Collaborator(s)N/A

EligibilityAll
18 Years and up
Not Recruiting